Clinical results of proton beam therapy for advanced neuroblastoma

Yoshiko Oshiro, Masashi Mizumoto, Toshiyuki Okumura, Shinji Sugahara, Takashi Fukushima, Hitoshi Ishikawa, Tomohei Nakao, Takayuki Hashimoto, Koji Tsuboi, Haruo Ohkawa, Michio Kaneko, Hideyuki Sakurai

Purpose: To evaluate the efficacy of proton beam therapy (PBT) for pediatric patients with advanced neuroblastoma. METHODS: PBT was conducted at 21 sites in 14 patients with neuroblastoma from 1984 to 2010. Most patients were difficult to treat with photon radiotherapy. Two and 6 patients were classified into stages 3 and 4, respectively, and 6 patients had recurrent disease. Seven of the 8 patients who received PBT as the initial treatment were classified as the high risk group. Eleven patients had gross residual disease before PBT and 3 had undergone intraoperative radiotherapy before PBT. Five patients received PBT for multiple sites, including remote metastases. Photon radiotherapy was used in combination with PBT for 3 patients. The PBT doses ranged from 19.8 to 45.5 GyE (median: 30.6 GyE). RESULTS: Seven patients are alive with no evidence of disease, 1 is alive with disease progression, and 6 died due to the tumor. Recurrence in the treatment field was not observed and the 3-year locoregional control rate was 82%. Severe acute radiotoxicity was not observed, but 1 patient had narrowing of the aorta and asymptomatic vertebral compression fracture at 29 years after PBT, and hair loss was prolonged in one patient. CONCLUSION: PBT may be a better alternative to photon radiotherapy for children with advanced neuroblastoma, and may be conducted safely for patients with neuroblastoma that is difficult to manage using photon beams.